C4 Therapeutics, Inc. (CCCC) Reports In-Line Q2 EPS

C4 Therapeutics, Inc. (NASDAQ: CCCC) reported Q2 EPS of ($0.36), in-line with the analyst estimate of ($0.36). Revenue for the quarter came in at $12 million versus the consensus estimate of $4.78 million.

For earnings history and earnings-related data on C4 Therapeutics, Inc. (CCCC) click here.

You May Also Be Interested In

• Cooper Cos. (COO) Tops Q3 EPS by 3c, Offers Guidance
• AeroVironment (AVAV) Tops Q1 EPS by 29c, Offers Guidance
• Evercore ISI Downgrades Chewy Inc. (CHWY) to In Line, 'Back on the Leash'